Mysimba (Bupropion Hydrochloride, Naltrexone Hydrochloride)

The combination pairs bupropion, which inhibits norepinephrine and dopamine reuptake, with naltrexone, an opioid receptor antagonist. Together they activate pro‑opiomelanocortin (POMC) neurons in the hypothalamus, enhancing satiety signals and increasing energy expenditure, which together promote weight loss.

The dosing regimen for Mysimba is individualized and set by a qualified prescriber. The physician will consider factors such as the patient’s weight, medical history, and response to therapy, and will titrate the dose according to approved prescribing information.

Safety data for Mysimba in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an enquiry, submit the required quantity on the Mysimba product page at gnhindia.com. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mysimba’s dual mechanism of norepinephrine‑dopamine reuptake inhibition plus opioid antagonism differs from agents that act solely on appetite pathways, such as GLP‑1 analogues. This unique synergy can offer additional weight‑loss benefit for patients who have not responded adequately to single‑target therapies.

Mysimba tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Mysimba is taken orally, usually once daily with food. The tablet is swallowed whole with a full glass of water. Patients should follow the titration schedule provided by their prescriber to minimize the risk of adverse effects.

The most serious risks include the potential for seizures, severe hypertension, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be monitored closely for any signs of these events and seek immediate medical attention if they occur.

Mysimba is contraindicated in individuals with a current seizure disorder, uncontrolled hypertension, or those taking monoamine oxidase inhibitors (MAOIs). It should also be avoided in patients with known hypersensitivity to bupropion, naltrexone, or any of the tablet’s excipients.